ScreenerHero

VXRTVaxart, Inc.

NAS · US · Healthcare · Biotechnology · vaxart.com
0.5200USD+6.10%Mkt Cap: 126.27M $P/E: 3.06

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap126.27M $
Enterprise Value74.76M $
Revenue (TTM)243.06M $
Gross Profit58.80M $
Net Income (TTM)16.33M $
Revenue/Share1.026 USD
Last Price0.5200 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees65
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)3.06
P/E (Forward)-0.50
PEG—
EV/EBITDA1.64
EV/Revenue0.31
P/S0.52
P/B1.33
EPS (TTM)0.18
EPS (Forward)-1.03
52W Range
0.310040% of range0.8400
52W High0.8400 USD
52W Low0.3100 USD
Profitability
Gross Margin24.19%
Oper. Margin-48.45%
EBITDA Margin18.77%
Profit Margin6.88%
ROE18.60%
ROA8.77%
Growth
Revenue Growth-31.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF7.71M $
CapEx (TTM)145.00K $
FCF Margin-7.06%
FCF Yield-13.58%
Net Debt-51.44M $
Net Debt/EBITDA-1.13
Balance Sheet
Debt/Equity0.10
Current Ratio1.60
Quick Ratio1.52
Book Value/Sh0.3900 USD
Cash/Share0.2630 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateNov 9, 2012
Pay DateFeb 14, 2018
Splits
Last Split1:11
Split DateFeb 14, 2018
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.333 USD
Upside (mean)+541.0%
Target Range2.000 USD – 4.000 USD
$2.000+541.0% to mean$4.000
# Analysts3
Ownership
Shares Out.242.84M
Float239.24M
Insiders1.39%
Institutions0.05%
Short Interest
Short Ratio2.6d
Short % Float9.40%
Short % Out.9.28%
Shares Short21.17M
Short (prev mo.)14.35M
Technical
SMA 500.5436 (-4.3%)
SMA 2000.5695 (-8.7%)
Beta1.07
S&P 52W Chg18.16%
Avg Vol (30d)137.90K
Avg Vol (10d)293.75K
Technical Indicators
RSI (14)46.9
MACD-0.0056
MACD Signal-0.0020
MACD Hist.-0.0036
BB Upper0.6202 USD
BB Middle0.5317 USD
BB Lower0.4431 USD
BB Width33.31%
ATR (14)0.0539 USD
Vol Ratio (20d)1.24x